Market Spotlight: Attention Deficit Hyperactivity Disorder (ADHD)

  • ID: 4489126
  • Report
  • 38 pages
  • Datamonitor Healthcare
1 of 3
This Market Spotlight report covers the Attention Deficit Hyperactivity Disorder (ADHD) market, comprising key pipeline and marketed drugs, clinical trials, upcoming and regulatory events, patent information, a 10-year disease prevalence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.sts.

Key Takeaways
  • The author estimates that in 2016, there were 175.1 million prevalent cases of attention deficit hyperactivity disorder (ADHD) in people aged 5-44 years worldwide, and forecasts that number to increase to 185.5 million prevalent cases by 2025.
  • The worldwide prevalence of ADHD among children aged 5-19 years is estimated to be 5.29%, while the prevalence among adults aged 20-44 years is estimated to be 2.80%.
  • The majority of approved drugs in the ADHD space target dopamine, dopamine reuptake, norepinephrine (noradrenaline), norepinephrine (noradrenaline) reuptake/transporter, and alpha 2 adrenergic receptor. Most of the drugs are commonly administered via the oral route, however, a few products are available in topical and intranasal formulations.
  • The majority of industry-sponsored drugs in active clinical development for ADHD are in Phase II. Therapies in mid-to-late stage development for ADHD focus on a wide variety of targets. Among these therapies, Benjorna (methylphenidate) is closest to market. The majority of the pipeline drugs in mid-to-late-stage development for ADHD are administered via the oral route.
  • High-impact upcoming events for drugs in the ADHD space include the US Food and Drug Administration’s decision on NDAs for Benjorna and dasotraline, and topline Phase II results for AEVI-001.
  • There were 14 licensing and asset acquisition deal agreements during 2013-17. Impax Laboratories’ acquisition of certain assets related to generic products from Teva and Allergan, for $586m, was the largest deal during the period.
  • Vyvanse’s (lisdexamfetamine dimesylate) sales have ranked highest in the ADHD space during 2012-16 and are forecast to remain the highest during the forecast period (2017-22).
  • The clinical trials distribution across Phase I-IV indicates that there is an even distribution of trials for ADHD, with 45.5% of trials in Phase I-II, and 54.5% in Phase III-IV.
  • The US has a substantial lead in the number of ADHD clinical trials globally. Germany leads the major EU markets, while Japan has the top spot in Asia.
  • Clinical trial activity in the ADHD space is dominated by completed trials. Shire has the highest number of completed clinical trials for ADHD, with 144 completed trials.
  • Shire has carried out the most Phase III trials in ADHD, followed by Eli Lilly, which has sponsored 50 Phase III trials.
READ MORE
Note: Product cover images may vary from those shown
2 of 3
1 KEY TAKEAWAYS

2 DISEASE BACKGROUND
  • ADHD Subtypes
3 TREATMENT
  • Non-pharmacological therapy
  • Pharmacological therapy
4 EPIDEMIOLOGY

5 MARKETED DRUGS
  • Approvals by country
6 PIPELINE DRUGS

7 KEY UPCOMING EVENTS

8 LICENSING AND ASSET ACQUISITION DEALS

9 PARENT PATENTS

10 REVENUE OPPORTUNITY

11 CLINICAL TRIAL LANDSCAPE
  • Sponsors by status
  • Sponsors by phase
  • Recent events
12 BIBLIOGRAPHY
  • Prescription information
13 APPENDIX

List of Figures
Figure 1: Trends in prevalent cases of ADHD, 2016-25
Figure 2: Pipeline drugs for ADHD in the US
Figure 3: Pipeline drugs for ADHD, by company
Figure 4: Pipeline drugs for ADHD, by drug type
Figure 5: Pipeline drugs for ADHD, by classification
Figure 6: Key upcoming events in ADHD
Figure 7: Licensing and asset acquisition deals in ADHD
Figure 8: Parent patents in ADHD
Figure 9: Clinical trials in ADHD
Figure 10: Top 10 drugs for clinical trials in ADHD
Figure 11: Top 10 companies for clinical trials in ADHD
Figure 12: Trial locations in ADHD
Figure 13: ADHD trials status
Figure 14: ADHD trials sponsors, by phase

List of Tables
Table 1: Prevalent cases of ADHD, 2016-25
Table 2: Marketed drugs for ADHD
Table 3: Approvals by country for ADHD
Table 4: Pipeline drugs for ADHD in the US
Table 5: Historical global sales, by drug ($m), 2012-16
Table 6: Forecasted global sales, by drug ($m), 2017-22
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
Note: Product cover images may vary from those shown
Adroll
adroll